Circulation Journal 2012-01-01

Intensive glucose lowering in cardiovascular risk management - unsolved questions - .

Michio Shimabukuro, Hiroaki Masuzaki, Masataka Sata

Index: Circ. J. 76(3) , 593-5, (2012)

Full Text: HTML

Structure	Name/CAS No.	Molecular Formula	Articles
	Nateglinide CAS:105816-04-4	C₁₉H₂₇NO₃
	D-Phenylalanine, N-[[4-(1-methylethyl)cyclohexyl]carbonyl]-, cis- CAS:105816-06-6	C₁₉H₂₇NO₃
	Voglibose CAS:83480-29-9	C₁₀H₂₁NO₇

Formulation and in vitro evaluation of nateglinide microsphe...
2013-11-01
[Pak. J. Pharm. Sci. 26(6) , 1229-35, (2013)]

From evidence assessments to coverage decisions?: the case e...
2012-01-01
[Health Policy 104(1) , 27-31, (2012)]

Nateglinide--current and future role in the treatment of pat...
2005-10-01
[Int. J. Clin. Pract. 59(10) , 1218-28, (2005)]

Efficacy and safety of mitiglinide versus nateglinide in new...
2012-02-01
[Diabetes Obes. Metab. 14(2) , 187-9, (2012)]

Nateglinide (Starlix): update on a new antidiabetic agent.
2003-01-01
[Int. J. Clin. Pract. 57(6) , 535-41, (2003)]